ArrowMark Partners

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

SmartLabs specializes in the design, construction, and operation of integrated, enterprise-grade research environments tailored for companies engaged in scientific discovery. The company provides multifunctional facilities, including research and development labs, vivariums, process development suites, and pilot-scale manufacturing areas. This comprehensive approach allows organizations of varying sizes and stages to initiate, expand, and adapt their research and development initiatives effectively. By colocating research infrastructure with manufacturing solutions, SmartLabs facilitates enhanced collaboration and access for all stakeholders involved in R&D and manufacturing, ultimately accelerating the development of effective therapeutics in the market.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. It specializes in the development of sustainable performance materials derived from microalgae and biobased oils. The company focuses on innovating materials at a molecular level, utilizing its expertise in molecular foundry, chemistry, material science, and fabrication technology. Checkerspot aims to expand the range of molecular building blocks available for high-performance materials, particularly in industrial applications such as polyurethanes and textile finishes. Through its pioneering approach, Checkerspot contributes to the advancement of sustainable materials in various industries.

Sonendo is a commercial-stage medical technology company that develops dental devices and software to save teeth. It markets the GentleWave System, a root canal therapy platform that cleans and disinfects the microscopic spaces within teeth without removing tooth structure, improving clinical outcomes and practice efficiency. The system includes a console and accessories and integrates with TDO Software, its endodontic practice management software that unifies imaging, practice management, referral reporting, CBCT imaging, and built-in communication with the GentleWave System. Founded in 2006 and based in Laguna Hills, California, Sonendo operates with two business segments: Product, comprising the GentleWave console and instruments, and Software, providing practice management licenses. The company aims to transform dentistry by saving teeth through sound science.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Starry, Inc. is an innovative internet company based in Boston, Massachusetts, with an additional operation in New York City. Founded in 2014, the company specializes in developing user-friendly Wi-Fi products and high-speed internet services. Its flagship product, Starry Station, is the first ambient touchscreen Wi-Fi router, designed to provide users with enhanced visibility and control over their home networks. In addition to its hardware, Starry employs advanced technologies to deliver high-speed broadband using hybrid-fiber fixed wireless solutions, offering gigabit-capable internet without the constraints of bundles, data caps, or long-term contracts. The company is committed to prioritizing customer needs, ensuring privacy, and promoting affordable connectivity and digital equity within communities.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapy for cancer treatment. Founded in 2018 and headquartered in New Haven, Connecticut, the company utilizes directed evolution to create novel cytokines that enhance the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor effects in animal models, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. This innovative approach aims to provide patients with more effective immunotherapies, thereby improving their ability to fight cancer.

Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.

Founded in 2010, Semasio specializes in targeting solutions for programmatic advertising. It uses Natural Language Processing to analyze website content, generating user profiles that enable clients to create and address specific audiences. Headquartered in Hamburg with offices in New York, Denmark, and Portugal, Semasio serves global agency networks, advertisers, and media agencies.

SmartLabs specializes in the design, construction, and operation of integrated, enterprise-grade research environments tailored for companies engaged in scientific discovery. The company provides multifunctional facilities, including research and development labs, vivariums, process development suites, and pilot-scale manufacturing areas. This comprehensive approach allows organizations of varying sizes and stages to initiate, expand, and adapt their research and development initiatives effectively. By colocating research infrastructure with manufacturing solutions, SmartLabs facilitates enhanced collaboration and access for all stakeholders involved in R&D and manufacturing, ultimately accelerating the development of effective therapeutics in the market.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Tvardi Therapeutics develops oral small molecule therapies targeting STAT3 for treating fibrosis-driven diseases such as idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

Latch is a technology company that provides an integrated smart building platform for multifamily properties. It deploys hardware and software to digitize building and unit access and in-unit device control, delivered via a cloud-based software-as-a-service platform known as the Latch Platform. The company offers products including cameras, locks, interconnects, and smart sensors that connect with the platform to manage access and building operations for owners, residents, guests, couriers, and service providers.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. It leverages its proprietary transgene regulation platform, EXACT, to create gene therapies with the aim of addressing high-need conditions. The company’s pipeline includes NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease. Founded in 2018, Neurogene is headquartered in New York and concentrates on advancing therapies that can improve outcomes for patients with limited treatment options.

Founded in 2011, Adagio Medical specializes in the research, development, and manufacturing of medical devices for treating cardiac arrhythmias. Its primary product is the iCLAS (continuous lesion ablation system), along with associated catheters, esophageal balloons, and consoles.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Shift is an online marketplace specializing in the buying and selling of used cars. The company acts as a personal concierge service, handling tasks such as detailing cars, listing them on multiple platforms, arranging test drives, and finding interested buyers. Shift charges customers a service fee for registration, car preparation services, and sales tax. Before purchase, customers receive a comprehensive 150-point concierge report that includes vehicle specifications, high-resolution photos, vehicle history, and inspection results.

Xometry offers an AI-enabled marketplace for on-demand manufacturing services, connecting buyers with manufacturers for efficient sourcing of parts and assemblies. Services include CNC machining, 3D printing, injection molding, urethane casting, die casting, and more.

Evolve Vacation Rental Network, Inc. operates a marketing and booking platform that specializes in vacation rental management services for homeowners and guests. Founded in 2010 and based in Denver, Colorado, Evolve enables homeowners to effectively market and book their vacation properties online. The company offers a range of services, including professional property listings, marketing, guest communications, and local service provider connections. Evolve distinguishes itself by providing homeowners with enhanced performance, lower fees, and greater flexibility compared to traditional property management approaches. Its network of vetted local partners ensures comprehensive support, covering aspects like housekeeping and maintenance. This model aims to maximize rental income for property owners while delivering a seamless travel experience for guests.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

SmartLabs specializes in the design, construction, and operation of integrated, enterprise-grade research environments tailored for companies engaged in scientific discovery. The company provides multifunctional facilities, including research and development labs, vivariums, process development suites, and pilot-scale manufacturing areas. This comprehensive approach allows organizations of varying sizes and stages to initiate, expand, and adapt their research and development initiatives effectively. By colocating research infrastructure with manufacturing solutions, SmartLabs facilitates enhanced collaboration and access for all stakeholders involved in R&D and manufacturing, ultimately accelerating the development of effective therapeutics in the market.

ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Inhibrx, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, that specializes in developing a diverse pipeline of novel biologic therapeutic candidates. The company's focus areas include oncology, orphan diseases, and infectious diseases, employing advanced protein engineering techniques, including its proprietary sdAb platform. Among its leading candidates is INBRX-109, a multivalent agonist of death receptor 5, currently in Phase 1 trials for treating solid tumors, including sarcomas. Another candidate, INBRX-105, serves as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB, also in Phase 1 trials for PD-L1 expressing tumors. Additional candidates include INBRX-101, aimed at alpha-1 antitrypsin deficiency, and INBRX-103, targeting cluster of differentiation 47. The company's preclinical programs encompass innovative therapies such as INBRX-106, a hexavalent agonist of OX40, and INBRX-111, a multifunctional antibody targeting Pseudomonas aeruginosa. Founded in 2010, Inhibrx has established collaborations with prominent organizations and received funding from various granting agencies.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

Evolve Vacation Rental Network, Inc. operates a marketing and booking platform that specializes in vacation rental management services for homeowners and guests. Founded in 2010 and based in Denver, Colorado, Evolve enables homeowners to effectively market and book their vacation properties online. The company offers a range of services, including professional property listings, marketing, guest communications, and local service provider connections. Evolve distinguishes itself by providing homeowners with enhanced performance, lower fees, and greater flexibility compared to traditional property management approaches. Its network of vetted local partners ensures comprehensive support, covering aspects like housekeeping and maintenance. This model aims to maximize rental income for property owners while delivering a seamless travel experience for guests.

Ascentage Pharma is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancers, hepatitis B virus (HBV), and age-related diseases. Its pipeline comprises seven drug candidates targeting protein-protein interactions and tyrosine kinases.

Convene LLC is a company that specializes in designing and servicing workspaces, meeting areas, and event venues. Founded in 2009 and headquartered in New York, it operates a network of co-working office spaces that cater to businesses and organizations. Convene offers a comprehensive suite of services, including conference rooms, event spaces, and dining options, supported by advanced technology for in-house production. The company combines elements of design, technology, and hospitality to create inspiring environments for collaboration and productivity. By providing end-to-end conference and collaboration services, Convene enables startups and established businesses to access well-equipped co-working spaces seamlessly.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Kodiak Sciences is a biopharmaceutical company focused on developing novel therapies for retinal diseases. Its lead product candidate, KSI-301, targets wet age-related macular degeneration and diabetic retinopathy. The company's pipeline also includes KSI-501, targeting inflammation and abnormal angiogenesis in retinal vascular diseases, and KSI-601 for dry AMD.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company has a diverse pipeline of clinical-stage product candidates, including Rilonacept, which is undergoing Phase III trials for recurrent pericarditis; Mavrilimumab, a monoclonal antibody in Phase II trials for giant cell arteritis; and KPL-716, currently in Phase 2a trials for prurigo nodularis and Phase 1a trials for atopic dermatitis. Kiniksa also has preclinical candidates, such as KPL-404, which targets the CD40/CD40L interaction in immune responses. Additionally, the company is collaborating with Kite Pharma to explore the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa Pharmaceuticals aims to address multiple autoimmune and autoinflammatory conditions through its innovative approaches.

Centrexion Therapeutics is a late-stage biopharmaceutical company dedicated to developing non-opioid, non-addictive therapies for chronic pain management. Its pipeline includes CNTX-4975 in Phase III trials for knee osteoarthritis pain, and other candidates in various stages of clinical development targeting diverse pain conditions.

NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focused on developing innovative immuno-therapeutics utilizing its proprietary Artificial Immune (AIM) technology. Founded in 2011, the company aims to enhance the immune system's response to various diseases, including cancer, inflammation, viral infections, transplant rejection, and autoimmunity. NexImmune's lead product candidates are AIM101, an aAPC-based injectable therapy targeting specific solid tumors, and AIM ACT, an adoptive cellular therapy for hematological malignancies. The AIM technology facilitates a controllable and reproducible immune response by leveraging the body's T cells to initiate targeted actions against specific antigens, even in conditions where natural antigen presenting cells are compromised. Currently, NexImmune is advancing its therapies through clinical trials, including NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma.

Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at revolutionizing cancer treatment. By harnessing the immune system's ability to recognize and attack neoantigens, the company seeks to develop innovative therapies that improve patient outcomes. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to enhance the immune response against tumors. Through its focused research and development efforts, Neon Therapeutics is committed to advancing the field of immuno-oncology and providing new options for cancer patients.

Intersection is a company that enhances urban experiences by providing programming, consumer amenities, and advertising in public spaces. It delivers connectivity, information, and content to engage people throughout their day.

Convene LLC is a company that specializes in designing and servicing workspaces, meeting areas, and event venues. Founded in 2009 and headquartered in New York, it operates a network of co-working office spaces that cater to businesses and organizations. Convene offers a comprehensive suite of services, including conference rooms, event spaces, and dining options, supported by advanced technology for in-house production. The company combines elements of design, technology, and hospitality to create inspiring environments for collaboration and productivity. By providing end-to-end conference and collaboration services, Convene enables startups and established businesses to access well-equipped co-working spaces seamlessly.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

Convene LLC is a company that specializes in designing and servicing workspaces, meeting areas, and event venues. Founded in 2009 and headquartered in New York, it operates a network of co-working office spaces that cater to businesses and organizations. Convene offers a comprehensive suite of services, including conference rooms, event spaces, and dining options, supported by advanced technology for in-house production. The company combines elements of design, technology, and hospitality to create inspiring environments for collaboration and productivity. By providing end-to-end conference and collaboration services, Convene enables startups and established businesses to access well-equipped co-working spaces seamlessly.

Twilio is a cloud-based communications company that empowers developers and businesses to build and integrate voice, video, messaging, and authentication into their applications via a robust set of APIs. By merging cloud computing, web services, and telecommunications, Twilio is transforming traditional telecom, enabling more contextual and personalized customer interactions. The company's Super Network ensures fast, cost-effective communication across the globe.

MarkLogic Corporation is a global enterprise software company specializing in data integration and management. It offers a unified NoSQL database platform that ingests, harmonizes, and analyzes complex data from diverse sources, enabling organizations to gain insights faster. The company's flagship product, MarkLogic Data Hub, simplifies data integration, reduces costs, and enhances agility. MarkLogic serves a wide range of industries, including finance, healthcare, government, and media, with clients such as major banks, pharmaceutical companies, and U.S. government agencies. Headquartered in San Carlos, California, MarkLogic has offices worldwide.

Sapphire Energy, Inc. is a pioneering company based in San Diego, California, that focuses on producing renewable solutions from algae. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, and non-arable land to cultivate algae in outdoor ponds, which generates biomass that can be transformed into high-value products, including oils, aquaculture and animal feeds, and renewable fuels. Sapphire Energy is unique in its approach, as its processes rely solely on photosynthetic microorganisms, distinguishing them from traditional biofuels that often depend on food crops. The company's products are designed to enhance and replace petroleum-based materials while being compatible with existing infrastructure. Sapphire operates a research and development facility in Las Cruces, New Mexico, and is developing an Integrated Algal BioRefinery in Columbus, New Mexico, with the aim of advancing the renewable energy landscape and contributing to a more sustainable planet.